Global investment manager Oaktree is out with its third life sciences-dedicated special purpose acquisition company after ...

A three-member committee appointed by the Department of Medical Education (DME) to probe into harassment allegations against ...

The creator economy has evolved significantly over the years. Today, creators are more than just content creators—they are ...

According to journalists, a 33-year-old battalion commander shot himself on October 2, after his battalion fled from ...

Heart disease is a type of cardiovascular disease that affects the heart’s structure and function. Several different heart ...

When you think of health care, what do you picture? Many of us see doctors in white coats and nurses wearing scrubs, but we don’t think of the people behind the scenes who ensure everything runs ...

Some of the notable companies in their portfolio include Hims & Hers, Vicarious ... The foundation provides scholarships, grants, and other support for education and youth programs. Additionally, he’s ...

find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs. Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your ...

I make the case that investors are not paying up for any GLP1 prospects, or even, for that matter, the actual core business that Hims & Hers (NYSE:HIMS) operates in. I argue that there's a lot ...

Hims & Hers (NYSE:HIMS), the telehealth platform that offers compounded versions of weight loss drugs, dropped more than 10% on Thursday after the FDA confirmed that Eli Lilly's (LLY) GLP-1 ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...

Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.S. Food and Drug Administration (FDA) that competitor Eli Lilly’s obesity and diabetes drugs are no longer ...